Atezolizumab (anti-PD-L1)

Product Name：Atezolizumab biosimilar

CAS No.:  1380723-44-3                               

Formula:   C₆₄₄₆H₉₉₀₂N₁₇₀₆O₁₉₉₈S₄₂                         

Molecular Weight：  145 kDa                  

Type:     Whole antibody                    

Target： PD-L1
Antibody Form:  Purified immunoglobulin
Physical Form:  Solution
Storage:  -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Description

Atezolizumab biosimilar is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab biosimilar is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa. 

Atezolizumab biosimilar is supplied at a concentration of 60 mg/mL as a sterile, preservative-free, colorless to slightly yellow solution, which contains 16.5 mg/ mL glacial acetic acid, 62 mg/mL L-histidine, 821.6 mg/mL sucrose, 8 mg/mL polysorbate 20, pH 5.8.

Biological Activity
Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction ofPD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1

For research use only. Not for use in humans